Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
point decrease » point increase (Expand Search)
part decrease » bfrt decreased (Expand Search), a decrease (Expand Search), pa decreased (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
point decrease » point increase (Expand Search)
part decrease » bfrt decreased (Expand Search), a decrease (Expand Search), pa decreased (Expand Search)
-
1921
-
1922
Incidence number, ASIR under the age of 20 in 204 countries and territories in 2021.
Published 2025Subjects: -
1923
-
1924
DALYs number, ASDR under the age of 20 in 204 countries and territories in 2021.
Published 2025Subjects: -
1925
-
1926
-
1927
-
1928
-
1929
-
1930
-
1931
-
1932
-
1933
-
1934
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
Published 2024Subjects: -
1935
-
1936
CHAMPS pilot Hb dataset.
Published 2025“…Postmortem testing showed a significant decrease in hemoglobin concentrations compared to antemortem levels. …”
-
1937
-
1938
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1939
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1940
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”